

- because cancer patients are individuals

Application of IndiTreat[®]

Henrik Harling, MD DMSci 2cureX Chief Medical Officer





Current chemotherapy of metastatic colorectal cancer

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Christophe Tournigand¹, Thierry André, Emmanuel Achille, Gérard Lledo, Michel Flesh, Dominique Mery-Mignard, Emmanuel Quinaux, Corinne Couteau, Marc Buyse, Gérard Ganem, Bruno Landi, Philippe Colin, Christophe Louvet, Aimery de Gramont

J Clin Oncol 2004;22: 229-37



Resistance to treatment with FOLFOX and FOLFIRI



1st line treatment

2nd line treatment

What if we could better predict response rate in chemo-naïve patients?




IndiTreat[®] the world`s first IVD CE validated cancer sensitivity test

A cancer sensitivity test based on patient derived microtumors which match a patient to a drug by directly testing their live tumor tissue.

Ineffective medical treatment

Effective medical treatment selected by IndiTreat[®]






Functional microtumor response (IndiTreat[®]) to 1L regimens in colorectal cancer





- because cancer patients are individuals

IndiTreat testing in third-line metastatic colorectal cancer



The power of functional and genomic precision

IndiTreat®

NGS

IndiTreat supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity





The power of precision. For every Oncologist. Today.

- because cancer patients are individuals